Page 25 - Pharmaceutical Firms

Preliminary report suggests lapse in manufacturing process at Maiden Pharma

The firm has been in news for supplying contaminated cough syrups to Gambia, which is linked to the deaths of 66 children due to the presence of contaminants

New Jersey-based Amneal Pharma starts mfg operations for Indian market

The firm already has manufacturing units in four Indian cities, all of which are focused on the export market

Existing pharma marketing practices code is adequate: Centre tells SC

Says Indian Pharmaceutical Alliance's investigation report cleared Dolo-650 maker, Micro Labs, of allegations of bribing doctors with freebies worth Rs 1,000 crore

Pharma industry says taking steps to check misuse of codeine drugs

Sales declining anyway and there is no need to ban because of alleged misuse, say experts

Udaan starts multiple deliveries per day for pharmacies in six cities

Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...

Pharma supply start-up Saveo Healthcare raises $4.5mn in venture round

Company founded by 4 IIT graduates will use money to expand its presence and for improving technology

Torrent Pharma acquires cosmetic derma player Curatio for Rs 2,000 cr

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Land parcels of pharma PSUs find no takers, but momentum likely in few mths

In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process

Mankind Pharma files for IPO, could be second largest among pharma firms

The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources

The SSI Mantra: India's own surgical robot boasts cheaper price tag

SSI Mantra has already been used for 22 complex procedures at Delhi hospital

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Essential medicines list updated, adds 34 new drugs and drops 26

Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Zenara Pharma launches nirmatrelvir, ritonavir tablets for Covid patients

Zenara Pharma on Friday announced the launch of nirmatrelvir and ritonavir tablets in a combination pack to be used as a treatment option for patients with mild-to-moderate symptoms of COVID-19. The company received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month, Zenara Pharma said in a statement. The drug will be sold under the brand name 'Paxzen' and is priced at Rs 5,200 per pack containing 20 tablets of nirmatrelvir 150 mg and 10 tablets of ritonavir 100 mg, which is equivalent to one full course of treatment for a patient, it added. It will be manufactured at Zenara's USFDA and EU-approved facility in Hyderabad, the company said. "Our product Paxzen has been proven equivalent to Paxlovid through a bioequivalence study, based on which we have received the approval from the regulatory authorities," Zenara Pharma co-founder and Managing Director, Jagadeesh Babu Rangisetty said. The USFDA had approved Paxlov

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

Sanofi may underperform in near term; pricing control among key risks

The decline was largely on account of divestment of its nutraceutical business and a few key brands.

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Lupin pharmaceutical inks licensing pact with Japan-based I'rom Group

Drug maker Lupin on Thursday said it has inked a licensing pact with Japan-based I'rom Group Co for a product used in the treatment of postmenopausal women with osteoporosis, among others. Under the terms of the agreement, I'rom along with the Mumbai-based drugmaker will conduct clinical trials, register, distribute and market biosimilar Denosumab in Japan on an exclusive basis. Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-related events in patients with bone metastases from solid tumours, among other indications. Following the completion of the clinical trial and receipt of marketing authorisation in Japan, I'rom will commercialise the product in the island nation, Lupin said in a statement. As part of the agreement, the drug maker will receive multiple milestone payments, it added. Currently, Denosumab is available under two brands, Pralia and Ranmark, with market size of about USD 500 mill

DOLO-650 makers distributed freebies worth Rs 1,000 cr to doctors: FMRAI

The petitioner, while seeking statutory backing to the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), said that corruption in pharma marketing practices is yet unregulated in India

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021